Virus Or Bacteriophage, Except For Viral Vector Or Bacteriophage Vector; Composition Thereof; Preparation Or Purification Thereof; Production Of Viral Subunits; Media For Propagating Patents (Class 435/235.1)
  • Patent number: 11684666
    Abstract: Provided here are certain recombinant HIV compositions and animal models to evaluate prophylactic and therapeutic antiviral compositions.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: June 27, 2023
    Assignee: University of Louisiana at Lafayette
    Inventors: Ruth M. Ruprecht, Samir K. Lakhashe
  • Patent number: 11684637
    Abstract: Disclosed are engineered oncolytic viruses, related fusion proteins and polynucleotides encoding them, and methods for treating cancer using the engineered viruses. In one aspect, disclosed herein are engineered oncolytic viruses, wherein the oncolytic virus expresses one or more exogenous membrane bound immune cell targeting ligands comprising an uncleaved signal anchor.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: June 27, 2023
    Assignee: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Griffith Parks, Alicja Copik
  • Patent number: 11684919
    Abstract: Methods for screening a plurality of sample fluids for molecules which can bind to predefined ligands, comprising, selecting one of a plurality of flow cell groups by fluidly connecting the selected flow cell group to a sample delivery unit; injecting a sample fluid to be screened from the sample delivery unit into the flow cells in the selected flow cell group; for each flow cell in the selected flow cell group, recording a signal using a sensor which represents the binding and/or the dissociation of molecules of the sample fluid to/from ligands on the test surface of that flow cell; carrying out a damage assessment step using said recorded signals; if it is determined that the test surface of a flow cell in the selected flow cell group is damaged, then fluidly connecting the other flow cell group to the sample delivery unit. There is further provided assemblies which can be used to implement the afore-mentioned methods.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: June 27, 2023
    Assignee: Creoptix AG
    Inventor: Kaspar Cottier
  • Patent number: 11685932
    Abstract: The present invention relates to host cells comprising a nucleic acid encoding Adeno-associated virus (AAV) Rep proteins Rep78 and Rep68, wherein the internal AAV promoter p19 has been inactivated by one or more mutations that maintain the functionality of said Rep78 and Rep68 proteins. The present invention further relates to respective nucleic acids and vectors comprising the same, as well as respective methods for the production of AAV.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: June 27, 2023
    Assignee: Cevec Pharmaceuticals, GmbH
    Inventors: Kerstin Hein, Nicole Faust, Silke Wissing
  • Patent number: 11679138
    Abstract: The present invention relates to a Myoviridae bacteriophage Vib-PAP-7 (Accession number: KCTC 13247BP) isolated from nature, which has the ability to kill Vibrio parahaemolyticus and has the genome represented by SEQ ID NO: 1, and a method for preventing or treating a disease caused by Vibrio parahaemolyticus using a composition containing the Myoviridae bacteriophage Vib-PAP-7 as an active ingredient.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: June 20, 2023
    Assignee: Intron Biotechnology, Inc.
    Inventors: Seong Jun Yoon, Soo Youn Jun, An Sung Kwon, Hyun Min Song, Eun Ji Lee, Sang Hyeon Kang
  • Patent number: 11680274
    Abstract: A method of correcting singletons in a selected AAV sequence in order to increasing the packaging yield, transduction efficiency, and/or gene transfer efficiency of the selected AAV is provided. This method involves altering one or more singletons in the parental AAV capsid to conform the singleton to the amino acid in the corresponding position(s) of the aligned functional AAV capsid sequences.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: June 20, 2023
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Luk Vandenberghe, Guangping Gao, James M. Wilson
  • Patent number: 11679137
    Abstract: The present invention relates to Myoviridae bacteriophage Vib-PAP-4(Accession No. KCTC 13168BP), isolated from nature, which possesses ability to specifically kill Vibrio parahaemolyticus bacteria and has the genome represented by SEQ ID No: 1, and a method for preventing infection of Vibrio parahaemolyticus bacteria and treating infection of Vibrio parahaemolyticus baceteria, using a composition containing the bacteriophage as an effective ingredient.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: June 20, 2023
    Assignee: Intron Biotechnology, Inc.
    Inventors: Seong Jun Yoon, Soo Youn Jun, An Sung Kwon, Hyun Min Song, Soon Hye Hwang, Sang Hyeon Kang
  • Patent number: 11680248
    Abstract: The invention relates to the field of virology and tumor therapy. In particular, the present invention provides a recombinant herpes simplex virus (HSV) capable of specifically replicating at a high level in a tumor cell and effectively killing the tumor cell, but replicating at low levels in normal cells, thereby the recombinant herpes simplex virus of the present invention not only has high lethality against tumor cells, but also has significantly decreased side effects (especially neurotoxicity). Further, the present invention relates to a viral vector constructed based on the recombinant herpes simplex virus, a pharmaceutical composition comprising the recombinant herpes simplex virus or the viral vector, and the use of the recombinant herpes simplex virus or the viral vector. The recombinant herpes simplex virus of the present invention can be used to infect and kill tumor cells, and can be used for gene drug delivery into tumor cells for gene therapy.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: June 20, 2023
    Assignees: XIAMEN UNIVERSITY, YANG SHENG TANG COMPANY, LTD.
    Inventors: Chenghao Huang, Yong Luo, Quan Yuan, Jun Zhang, Ningshao Xia
  • Patent number: 11674157
    Abstract: Certain donor plasmid vectors such as pFastBac™1 and pFastBac™ Dual lack a cis DNA element upstream of the polh translation start codon (ATG) present in wild type (wt) Autographa californica multiple nucleopolyhedrovirus (AcMNPV), and contain a SV40 pA fragment. When a cis DNA element is inserted upstream of the 50 bp polh promoter and SV40 pA was replaced with a AcMNPV polh pA signal in pFastBac™1 and pFastBac™Dual, certain protein expression levels in High Five™ cells using the Bac-to-Bac® system reached that of the wt AcMNPV.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: June 13, 2023
    Assignee: Miami University
    Inventors: Xiao-Wen Cheng, Hui Shang, Tyler Garretson
  • Patent number: 11667672
    Abstract: The present disclosure pertains to filtration methods comprising: passing a first fluid that comprises cells, cell debris and targeted product produced by the cells through a first filter thereby separating the first fluid into a first retentate comprising cells and a first permeate comprising targeted product and cell debris; combining resin beads having affinity for targeted product with the first permeate to form a second fluid containing resin beads with bound target product and cell debris; passing the second fluid through a second filter thereby separating the second fluid into a second retentate comprising resin beads with bound target product and a second permeate comprising cell debris; combining an elution buffer with the second retentate to form a third fluid that comprises a mixture of resin beads and unbound targeted product; and passing the third fluid through a third filter thereby separating resin beads from targeted product.
    Type: Grant
    Filed: May 27, 2021
    Date of Patent: June 6, 2023
    Assignee: REPLIGEN CORPORATION
    Inventor: Michael Bransby
  • Patent number: 11654192
    Abstract: The present disclosure concerns an oncolytic virus for the treatment of cancer, such as in brain cancer, for example glioblastoma. The oncolytic virus may exhibit reduced levels of neurotoxicity. The oncolytic virus may be an isolated viral particle capable of producing a cDNA polynucleotide that includes a sequence according to SEQ ID NO: 1 when the virus is in a host cell. The oncolytic virus may be an isolated viral particle that includes an RNA polynuclotide that includes a sequence according to SEQ ID NO: 2. The oncolytic virus may be an isolated viral particle having a genome that includes open reading frames that encode: proteins having sequences comprising SEQ ID NOs: 3, 4, 5, 6 and 7; or variants thereof.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: May 23, 2023
    Assignee: CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC.
    Inventor: David F. Stojdl
  • Patent number: 11642407
    Abstract: Provided herein are universal prophylactic compositions for preventing infection with influenza viruses by directing the immune response to highly conserved regions of the virus. Also provided are universal therapeutic compositions for treating influenza infection by targeting the highly conserved regions. Methods for using the prophylactic and therapeutic compositions are also provided.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: May 9, 2023
    Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventor: Darrell O. Ricke
  • Patent number: 11629362
    Abstract: Provided are embodiments of replicative oncolytic adenovirus AD5 ApoA1 for inhibiting tumor growth and metastasis and use thereof in preparation of anti-tumor drugs. The virus can rapidly replicate in tumor cells and exert an oncolytic effect. Tumor cells infected with the virus can highly express apolipoprotein ApoA1 which can be secreted extracellularly in large quantities, significantly inhibit the invasion and metastasis of tumor cells, inhibit tumor-promoting inflammation pathways, and significantly reduce a IDO-1 which is a key molecule that leads to tumor immune escape. The virus can significantly inhibit tumor growth, inhibit tumor invasion, delay progression of cachexia and prolong the survival time of tumor-bearing mice in mice with liver cancer, breast cancer, colon cancer, or lung cancer.
    Type: Grant
    Filed: February 19, 2022
    Date of Patent: April 18, 2023
    Assignee: Nanjing Novel Biotechnology Co., Ltd
    Inventors: Jiwu Wei, Jie Dong, Tiancheng Xu, Lingkai Kong, Guanqun Wo
  • Patent number: 11629338
    Abstract: Disclosed is a second-order culture method for producing a suspended Vero cell vaccine, wherein same comprises the following steps: suspension culture growth of Vero cells, inoculation of a virus, dilution or addition of a production medium, secondary growth of cells, and optionally harvesting and purifying the virus fluid to produce the vaccine.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: April 18, 2023
    Assignee: JIANSHUN BIOSCIENCES CO., LTD.
    Inventors: Shijun Cai, Ruijuan Hou
  • Patent number: 11624070
    Abstract: Compositions and methods for modifying genomic DNA sequences are provided. The methods produce double-stranded breaks (DSBs) at pre-determined target sites in a genomic DNA sequence, resulting in mutation, insertion, and/or deletion of DNA sequences at the target site(s) in a genome. Compositions comprise DNA constructs comprising nucleotide sequences that encode a Cms1 protein operably linked to a promoter that is operable in the cells of interest. The DNA constructs can be used to direct the modification of genomic DNA at pre-determined genomic loci. Methods to use these DNA constructs to modify genomic DNA sequences are described herein. Additionally, compositions and methods for modulating the expression of genes are provided.
    Type: Grant
    Filed: September 29, 2020
    Date of Patent: April 11, 2023
    Assignee: BENSON HILL, INC.
    Inventors: Matthew Begemann, Benjamin Neil Gray
  • Patent number: 11620750
    Abstract: System, method and computer readable medium that assess characteristics of an embryo by processing video image data of the embryo. Video is obtained, typically from third parties, of a target embryo. The video has frame speed of two frames per second, or faster and includes image data representing morphokinetic movement of the embryo. The image data is processed using a trained machine learning model that assesses embryo characteristics. The video has a duration of ten minutes or less. The assessment can be a prediction of a likelihood the embryo is viable and/or will produce a pregnancy upon transfer into a recipient. Further, the assessment can predict a likelihood the embryo will: (1) produce offspring having a specific sex; (2) embody a genetic anomaly; (3) perpetuate desired traits in produced offspring and/or (4) produce undesired characteristics in produced offspring.
    Type: Grant
    Filed: July 15, 2022
    Date of Patent: April 4, 2023
    Assignee: Emgenisys, Inc.
    Inventors: Cara Elizabeth Wessels Wells, Russell Killingsworth
  • Patent number: 11613561
    Abstract: Synthetic alphavirus-derived replicon expression systems comprising nucleic acid sequences encoding at least one modified nonstructural protein, and synthetic nucleic acid sequences encoding at least one heterologous protein are described. Methods of producing at least one heterologous protein in a cell, or of inducing an immune response in a subject by administering and/or expressing the synthetic alphavirus-derived replicon expression systems are provided.
    Type: Grant
    Filed: March 18, 2022
    Date of Patent: March 28, 2023
    Assignee: TIBA BIOTECH, LLC
    Inventors: Jasdave S Chahal, Justine S McPartlan
  • Patent number: 11614437
    Abstract: In an aspect, disclosed herein are physiological devices and systems, and components thereof, used to evaluate cardiac parameters and arrhythmogenic mechanisms. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: March 28, 2023
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: James Hickman, Maria Stancescu, Peter Molnar, Christopher Long, Christopher McAleer
  • Patent number: 11613759
    Abstract: The present disclosure pertains to methods for delivering a compound into a cell comprising a cell wall, including passing a cell suspension through a constriction, wherein said constriction deforms the cell comprising a cell wall, thereby causing a perturbation of the cell such that the compound enters the cell, wherein said cell suspension is contacted with the compound.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: March 28, 2023
    Assignee: SQZ Biotechnologies Company
    Inventors: Armon R. Sharei, Howard Bernstein, Jonathan B. Gilbert
  • Patent number: 11608510
    Abstract: The present invention relates to variant AAV capsid polypeptides, wherein the variant AAV capsid polypeptides exhibit increased transduction and/or tropism in human pancreatic tissue or human islets as compared non-variant parent capsid polypeptides.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: March 21, 2023
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Katja Pekrun, Mark A. Kay
  • Patent number: 11608570
    Abstract: The present invention relates to a method for producing a panel of cells (i.e. a cell library) expressing various different mutant variants of a protein of interest, wherein only one of said mutant variants is expressed per cell from a single gene copy. The present invention also relates to a method or cell library for identifying a mutant variant of a protein of interest having a different or modified biological activity as compared to the corresponding wild-type protein of interest. According to the present invention the identified mutant variant of a protein of interest may be applied for white biotechnology.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: March 21, 2023
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V.
    Inventors: David Ng, Oliver Griesbeck, Mutlu Erdogan
  • Patent number: 11603519
    Abstract: Provided is a T cell receptor capable of binding to a peptide having the amino acid sequence shown in SEQ ID NO: 27 or a complex of the peptide and HLA-A24. A T cell receptor capable of binding to a peptide having the amino acid sequence shown in SEQ ID NO: 28 or a complex of the peptide and HLA-A02. Disclosed T cell receptors are useful in treating or avoiding cancers which are associated with expression of glypican-3.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: March 14, 2023
    Assignees: National Cancer Center Japan, Kyoto University, Takeda Pharmaceutical Company Limited
    Inventors: Tetsuya Nakatsura, Toshiaki Yoshikawa, Yasushi Uemura, Kyoko Fukuda, Shin Kaneko, Atsutaka Minagawa, Yoshiaki Kassai, Atsushi Matsuda
  • Patent number: 11591619
    Abstract: Compositions include modified adenoviruses. Nucleotides, cells, and methods associated with the compositions, including their use as vaccines. Viral vectors using a TET promoter system and methods of producing viruses having the same.
    Type: Grant
    Filed: November 30, 2021
    Date of Patent: February 28, 2023
    Assignee: GRITSTONE BIO, INC.
    Inventors: Karin Jooss, Ciaran Daniel Scallan, Leonid Gitlin
  • Patent number: 11584936
    Abstract: The present disclosure provides a viral-mediated genome-editing platform that facilitates multiplexing, obviates stable transformation, and is applicable across plant species. The RNA2 genome of the tobacco rattle virus (TRV) was engineered to carry and systemically deliver a guide RNA molecules into plants overexpressing Cas9 endonuclease. High genomic modification frequencies were observed in inoculated as well as systemic leaves including the plant growing points. This system facilitates multiplexing and can lead to germinal transmission of the genomic modifications in the progeny, thereby obviating the requirements of repeated transformations and tissue culture. The editing platform of the disclosure is useful in plant genome engineering and applicable across plant species amenable to viral infections for agricultural biotechnology applications.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: February 21, 2023
    Assignee: KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Magdy M. Mahfouz, Zahir Ali
  • Patent number: 11583563
    Abstract: Adeno-associated liquid and lyophilized pharmaceutical compositions are provided herein. In exemplary aspects, the pharmaceutical compositions comprise about 5 mM to about 25 mM L-histidine, about 0 mM to about 150 mM sodium chloride, about 0.001% (w/v) to about 0.01% (w/v) polysorbate 80 (PS80), and about 1% to about 10% (w/v) sucrose, trehalose, or combination thereof to AAV. In exemplary aspects, the pharmaceutical compositions further comprise glycine or mannitol. Methods of preparing a pharmaceutical composition comprising AAV, methods of treating a bleeding disorder in a subject, and methods of storing AAV compositions are also provided.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: February 21, 2023
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Christian Fiedler, Eva Fritscher, Meinhard Hasslacher, Dominik Mittergradnegger, Tanvir Tabish
  • Patent number: 11576963
    Abstract: The present invention provides compositions and methods related to equine live-attenuated influenza vaccines.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: February 14, 2023
    Assignee: University of Rochester
    Inventors: Luis Martinez-Sobrido, Thomas Chambers
  • Patent number: 11572637
    Abstract: Disclosed herein are methods of high-throughput mapping of viral neutralizing antibody epitopes. Also disclosed are in vitro immunoprecipitation-based adeno-associated virus Barcode-Seq-based methods of mapping viral neutralizing antibody epitopes. In some embodiments, a method of high-throughput mapping of viral NtAb conformational epitopes can be utilized, which may comprise HP scanning of mutant viral libraries, immunoprecipitation (IP), and/or next-generation sequencing (NGS) technology. In some embodiments, a method of identifying one or more dominant epitopes in a viral vector may comprise contacting a mutant capsid of a virus with serum from a subject previously exposed to the virus and immunoprecipitating serum immunoglobulins from the serum. In various embodiments, the viral vector may be an AAV vector.
    Type: Grant
    Filed: July 7, 2020
    Date of Patent: February 7, 2023
    Assignee: Oregon Health & Science University
    Inventors: Hiroyuki Nakai, Kei Adachi
  • Patent number: 11554179
    Abstract: The present invention provides a novel lyophilized pharmaceutical composition that maintains the stability of a DNA plasmid while forming a uniform and elegant cake during lyophilization. The novel lyophilization formulation further allows uniform reconstitution of the DNA plasmid in a pharmaceutically acceptable solution, enabling complete recover of the active ingredients, minimizing partial loss of potency and allowing administration of the active ingredients in an accurate and consistent manner. Additionally provided herein include methods of making the lyophilized pharmaceutical composition and methods of administering the composition for treatment of various diseases.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: January 17, 2023
    Assignee: Helixmith Co., Ltd
    Inventor: Byeong Seon Chang
  • Patent number: 11549154
    Abstract: Provided are compositions and methods useful to the determination of whether a microbial contaminant is present in a biological therapeutic production process. Specifically, an artificial positive amplification control plasmid and unique quantitative PCR detection probe are provided, which enables the rapid and real-time detection of a false positive result.
    Type: Grant
    Filed: April 22, 2020
    Date of Patent: January 10, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Serge Monpoeho, Sheldon Mink, Paul Vescio
  • Patent number: 11535867
    Abstract: Provided herein are methods related to co-packaging of multiple rAAV particles, e.g., by introducing multiple nucleic acid vectors encoding proteins or polypeptides or RNAs of interest into a single cell preparation.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: December 27, 2022
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Barry John Byrne, Phillip A. Doerfler, Nathalie Clement
  • Patent number: 11512115
    Abstract: The present invention relates i.a. to a recombinant avian coronavirus spike protein or fragment thereof comprising a mutation at amino acid position 267 to Cysteine. Further, the present invention relates to an immunogenic composition comprising an avian coronavirus with such spike protein.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: November 29, 2022
    Inventors: Annika Kraemer-Kuehl, Thomas Min Stephan, Hans-Christian Philipp
  • Patent number: 11497808
    Abstract: Provided are HBV immunogenic polypeptides, polynucleotides encoding such polypeptides, vectors expressing such immunogenic polypeptides for use in eliciting an immune response against HBV; pharmaceutical and immunogenic compositions and kits comprising such polypeptides, polynucleotides or vectors, and methods of use in treating and/or preventing HBV.
    Type: Grant
    Filed: September 28, 2020
    Date of Patent: November 15, 2022
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Scott J. Balsitis, Sarah M. Ahmadi-Erber, Timo Schippers, Sarah Schmidt
  • Patent number: 11491217
    Abstract: The present disclosure relates to Zika vaccines. In certain embodiments, this disclosure relates to vaccine compositions for use in methods of protecting a human subject against Zika disease or infection, wherein said composition comprises a vaccinal for Zika such as a live attenuated or inactivated chimeric Zika virus; live attenuated Zika virus; an inactivated Zika virus; a replication-defective pseudo-infectious Zika virus; a Zika virus-like particle (VLP), a Zika protein or combinations thereof. In certain embodiments, the Zika vaccinal comprises or encodes altered polypeptide sequences disclosed herein.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: November 8, 2022
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventor: Baek Kim
  • Patent number: 11478517
    Abstract: The present application generally relates to the development of live attenuated Pneumoviridae strains suitable for use as a vaccine. Particularly, human metapneumovirus (hMPV) ?M2-2 strains (rhMPV-E30M31 and rhMPV-E40L42D44) containing point mutations in a PDZ motif of M2-2, which results in a strain that is both attenuated and immunogenic and, notably, maintains the function of F and G proteins. These live attenuated hMPV strains should be suitable for use in a vaccine capable of providing protection against respiratory infection elicited by hMPV. Additionally, human respiratory syncytial virus (hRSV) strains containing point mutations in a PDZ motif of M2-2 should also be suitable for use as a vaccine capable of providing protection against respiratory infection elicited by hRSV. These Pneumoviridae strains should be useful in vaccines for use in humans and animals, e.g., companion animals and livestock, in treating or providing immunoprotection against respiratory infections.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: October 25, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventor: Xiaoyong Bao
  • Patent number: 11471521
    Abstract: The invention relates to a live-attenuated yellow fever virus strain adapted to grow on Vero cells from a parent yellow fever virus 17D substrain that is not adapted to grow on Vero cells, wherein said live-attenuated yellow fever virus strain is less neurovirulent than said parent yellow fever virus 17D substrain.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: October 18, 2022
    Assignee: Sanofi Pasteur
    Inventors: Manuel Vangelisti, Nathalie Mantel, Yves Girerd-Chambaz, Fabienne Piras
  • Patent number: 11471489
    Abstract: Provided herein are binding molecules, such as those that recognize or bind a peptide epitope of a cancer antigen, such as expressed on a cancer cell, including cells infected with human papilloma virus (HPV) or that contain HPV DNA sequences and/or those that recognize or bind a peptide epitope of HPV 16 E6 or E7, in the context of a major histocompatibility complex (MHC) molecule. Among the provided binding molecules are T cell receptors (TCRs) or antibodies, including antigen-binding fragments thereof, that bind or recognize such peptide epitopes. The present disclosure further relates to engineered cells comprising such binding molecules, e.g., TCRs or antibodies (and chimeric antigen receptors containing the antibodies), and uses thereof in adoptive cell therapy.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: October 18, 2022
    Assignee: Juno Therapeutics, Inc.
    Inventors: Stephen Jacob Goldfless, Brian Belmont, Cameron Brandt, Alexandra Croft, David Jeffrey Huss
  • Patent number: 11452772
    Abstract: The invention relates to a live-attenuated yellow fever virus strain adapted to grow on Vero cells from a parent yellow fever virus 17D substrain that is not adapted to grow on Vero cells, wherein said live-attenuated yellow fever virus strain is less neurovirulent than said parent yellow fever virus 17D substrain.
    Type: Grant
    Filed: November 5, 2021
    Date of Patent: September 27, 2022
    Assignee: Sanofi Pasteur
    Inventors: Manuel Vangelisti, Nathalie Mantel, Yves Girerd-Chambaz, Fabienne Piras
  • Patent number: 11406690
    Abstract: The present disclosure provides methods of generating multiplexed genetically modified animals, for example, porcine endogenous retrovirus (PERV)-inactivated pigs. The disclosure also provides methods of improving the birth rate of multiplexed genetically modified animals. In some embodiments, the present closure is concerned with the generation and utilization of porcine cells in which porcine endogenous retroviral (PERV) elements have been inactivated. In sonic embodiments, the PERV-free or PERV-reduced porcine cells are cloned to produce porcine embryos. In some embodiments, the PERV-free or PERV-reduced embryos may be grown into adult swine from which organs and/or tissues may be extracted and used for such purposes as xenotransplantation into non-porcine animals such as humans.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: August 9, 2022
    Assignees: BIOMARIN PHARMACEUTICAL INC., UCL BUSINESS LTD, ST. JUDE CHILDREN'S RESEARCH HOSPITAL
    Inventors: Peter Cameron Colosi, Amit Nathwani, Jenny McIntosh, Edward Tuddenham, Andrew Davidoff
  • Patent number: 11400150
    Abstract: The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines,
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: August 2, 2022
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Government of the United States, as Represented by The Secretary of The Army
    Inventors: Alexander G. Pletnev, Joseph R. Putnak, Robert M. Chanock, Brian R. Murphy, Stephen S. Whitehead, Joseph E. Blaney
  • Patent number: 11378565
    Abstract: A method for in-ova fertilisation determination and gender determination on a closed egg. The aim is to specify a method for the in-ovo fertilisation determination and gender determination on a closed egg. This aim is achieved by a method in which a closed egg is positioned, candled and/or illuminated, next an image of the closed egg is recorded, then the captured data are evaluated and the position of the cardiovascular system located in the egg is calculated. A detection unit is adjusted via the calculated position of the cardiovascular system by means of a positioning unit and subsequently the blood is stimulated, then the blood-specific and blood-foreign absorption spectra are detected and selected, the fertilisation is ascertained and then the spectra containing blood-foreign information are compensated by a compensation method and the spectra are classified for sex determination.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: July 5, 2022
    Assignee: Technische Universität Dresden
    Inventors: Grit Preusse, Gerald Steiner, Roberta Galli, Edmund Koch, Christian Schnabel
  • Patent number: 11352439
    Abstract: Modified macrophage immune cells are provided for treatment of cancer and other diseases.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: June 7, 2022
    Inventors: Kim Leslie O'Neill, Scott Weber
  • Patent number: 11351243
    Abstract: The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, methods to make it and related polypeptides, polynucleotides, and various components. Vaccines comprising the genetically modified virus and polynucleotides and a diagnostic kit to distinguish between naturally infected and vaccinated animals are also provided.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: June 7, 2022
    Assignee: Zoetis Services LLC
    Inventors: Jay Gregory Calvert, David Ewell Slade, Siao-Kun W. Welch
  • Patent number: 11340238
    Abstract: The present invention provides an in vitro method for detecting the presence of neutralizing antibodies against recombinant human insulin (rHI) in human serum. It also provides a kit for an in vitro method of detection of the presence of recombinant human insulin (rHI) neutralizing antibodies.
    Type: Grant
    Filed: October 15, 2016
    Date of Patent: May 24, 2022
    Assignee: BIOCON LIMITED
    Inventors: Abhishek Kulshrestha, Ravi Shankar Maurya, Sudeep Sabde, Pallavi Hajela, Pawan Kalani, Ramakrishnan Melarkode, Narendra Chirmule
  • Patent number: 11306291
    Abstract: The present invention relates to production of proteins in insect cells whereby repeated coding sequences are used in baculoviral vectors. In particular the invention relates to the production of parvoviral vectors that may be used in gene therapy and to improvements in expression of the viral rep proteins that increase the productivity of parvoviral vectors.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: April 19, 2022
    Assignee: UNIQURE IP B.V.
    Inventors: Andrew Christian Bakker, Wilhelmus Theodorus Johannes Maria Christiaan Hermens
  • Patent number: 11299752
    Abstract: The present disclosure provides a method of generating a stable producer cell line. The generation of stable producer cell lines, such as those provided in accordance with the present invention, increases the reproducibility and ease of creating high titer lentiviral stocks while easing biosafety concerns and the variation in expressed envelope proteins defines the tropism of the generated virus. The present disclosure also provides for a novel lentiviral transfer vector plasmid.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: April 12, 2022
    Assignee: CSL Behring Gene Therapy, Inc.
    Inventors: Chi-Lin Lee, Jeffrey S Bartlett
  • Patent number: 11299715
    Abstract: The use of iNOS inhibitors, including aurintricarboxylic acid, dexamethasone and valproic acid, to increase the yield of a variety of viruses in culture, including recombinant herpesviruses is described.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: April 12, 2022
    Assignee: Genzyme Corporation
    Inventors: Peter Pechan, Jeffery Ardinger, Abraham Scaria, Samuel Wadsworth
  • Patent number: 11286500
    Abstract: A nucleic acid molecule can code for an Orf virus vector promoter. A recombinant Orf virus vector can be included in a cell. The nucleic acid molecule, the vector and/or the cell can be included in a composition. The recombinant Orf virus vector can be used for the production of a foreign gene.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: March 29, 2022
    Assignee: EBERHARD KARLS UNIVERSITÄT TÜBINGEN MEDIZINISCHE FAKULTÄT
    Inventors: Hanns-Joachim Rziha, Ralf Amann
  • Patent number: 11273127
    Abstract: Embodiments of the present invention provide for novel compositions and methods for making and using a thermally stable human papilloma virus (HPV) formulation or other stabilized multimeric virus formulation. Certain embodiments concern lyophilizing HPV formulations in the presence or absence of adjuvants. Other embodiments concern lypophilizing HPV capsomere vaccines in order to increase stability of an immunogenic composition against HPV infection for storage, delivery and use. In yet other embodiments, a single immunogenic composition can include a thermally stable formulation of multiple virus serotypes. Yet other embodiments disclosed herein concern multi-targeted antigen complexes lyophilized in formulations of use to prolong stability and/or enhance immunogenicity. Other embodiments concern exposing lyophilized multi-targeted antigen complexes to elevated temperatures to enhance immunogenicity of the antigens of the complex to multiple pathogens.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: March 15, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Theodore Randolph, Robert Garcea
  • Patent number: 11268116
    Abstract: Disclosed are methods and kits for endonuclease-assisted DNA amplification reaction using decontaminated primer solutions that are pre-treated with a nuclease. Nucleic acid amplification assays that employ nuclease-resistant, inosine-containing primers, endonuclease V enzymes to introduce a nick into a target DNA comprising at least one inosine, and a DNA polymerase to generate amplicons of a target DNA are also disclosed.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: March 8, 2022
    Assignee: GLOBAL LIFE SCIENCES SOLUTIONS OPERATIONS UK LTD
    Inventors: Robert Scott Duthie, John Richard Nelson, Anuradha Sekher
  • Patent number: 11261416
    Abstract: We have modified a commercially-available adherent cell culture bioreactor in several ways to increase productivity of cultured cells, while decreasing contamination risk. We found that modifying a commercially-available adherent cell culture bioreactor to provide for slower cell culture medium flow unexpectedly and dramatically increases the productivity of the cultured adherent cells. We also developed a new sampling manifold configuration and new way of taking samples, to reduce contamination risk.
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: March 1, 2022
    Assignee: Trizell Ltd.
    Inventors: Piia Kristiina Valonen, Hanna P. Lesch, Eva Kristiina Rasanen, Tarja Hannele Tuunanen, Minna Kristiina Karhinen, Seppo Yla-Herttuala